Baminercept alfa manufacturers
- Baminercept
-
- $330.00
-
2026-07-27
- CAS:909110-25-4
- Purity: 95% (SDS-PAGE); 98.3% (SEC-HPLC)
- Supply Ability: 10g
|
| | Baminercept alfa Basic information |
| Product Name: | Baminercept alfa | | Synonyms: | Baminercept alfa;Research Grade Baminercept Alfa (DHB94302);Research Grade Baminercept Alfa;Baminercept | | CAS: | 909110-25-4 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Baminercept alfa Structure]() |
| | Baminercept alfa Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Baminercept alfa Usage And Synthesis |
| Uses | Baminercept (BG 9924) is an anti-lymphotoxin β receptor (LTβR) IgG fusion protein (LTβR-Ig). Baminercept selectively binds to the LTβR ligand LTα/β heterotrimer and LIGHT, block the LTβR signaling pathway, and inhibits the expression of chemokines such as CXCL13. Baminercept also regulates peripheral blood B cell and T cell subsets, reduces the transcription of IFN-induced genes. Thereby Baminercept inhibits the formation of high endothelial venules and reticular structures in lymphoid tissues, and affects immune cell migration. Baminercept can be used for the study of autoimmune diseases such as primary Sjgren's syndrome (pSS) and rheumatoid arthritis (RA)[1][2]. | | References | [1] E William St Clair, et al. Clinical Efficacy and Safety of Baminercept, a Lymphotoxin β Receptor Fusion Protein, in Primary Sjgren's Syndrome: Results From a Phase II Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheumatol. 2018 Sep;70(9):1470-1480. DOI:10.1002/art.40513
[2] Jadwiga Bienkowska, et al. Lymphotoxin-LIGHT pathway regulates the interferon signature in rheumatoid arthritis. PLoS One. 2014 Nov 18;9(11):e112545. DOI:10.1371/journal.pone.0112545 |
| | Baminercept alfa Preparation Products And Raw materials |
|